Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Revenue of Instil Bio, Inc. (TIL)
Revenue in 2023 (TTM): $
According to Instil Bio, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Instil Bio, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-4,756,000 | $-85,785,000 | $-156,087,000 | $-156,087,000 |
| 2022 | $ | $-5,987,000 | $-200,200,000 | $-225,250,000 | $-223,177,000 |
| 2021 | $ | $-2,752,000 | $-155,560,000 | $-156,755,000 | $-156,794,000 |
| 2020 | $138 K | $138 K | $-34,031,000 | $-37,587,000 | $-37,738,000 |
| 2019 | $ | $-20,000 | $-6,565,000 | $-6,522,000 | $-6,454,000 |